Immunocore HIV cure candidate IMC-M113V shows dose-dependent viral control in Phase 1/2 MAD data at CROI 2025

Immunocore Holdings plc

Well tolerated across 60-300 mcg doses; no dose-limiting toxicities or serious AEs; mild CRS in 5 of 6 at 300 mcg.
3 of 15 evaluable PLWH showed delayed viral rebound or viremia control after ART interruption; 2 remained off ART for full 12 weeks.
Dose-dependent reduction in active reservoir (CD4+ Gag RNA) and trend of intact HIV DNA reduction at higher doses.
Enrollment continues with higher doses; expansion cohorts planned at one or more doses.
IMC-M113V is first TCR bispecific targeting HIV in clinic, aims for functional cure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.